| |
|
Product Name:
|
Western Reserve (NIAID, Tissue Culture Adapted)
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Virus Classification: Poxviridae, Orthopoxvirus
Species: Vaccinia virus
Strain: Western Reserve (NIAID, tissue culture adapted)1
|
|
Material Provided:
|
Each vial contains approximately 1 mL of cell lysate and supernatant from Chlorocebus aethiops kidney cells (Vero; ATCC® CCL-81™) infected with VACV, WR (NIAID, tissue culture adapted).
Note: If homogeneity is required for your intended use, please purify prior to initiating work.
|
|
Packing/Storage:
|
NR-55 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.
|
|
Growth Conditions:
|
Host: Chlorocebus aethiops kidney cells (Vero; ATCC® CCL-81™)
Growth Medium: Eagle's minimum essential medium modified to contain Earle's Balanced Salt Solution, non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1500 milligrams per liter sodium bicarbonate supplemented with 2% fetal bovine serum, or equivalent
Infection: Cells should be approximately 80 to 90% confluent
Incubation: 6 to 8 days at 37°C and 5% CO2
Cytopathic Effect: Cell rounding and detachment
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Parker, R. F., L. H. Bronson, and R. H. Green. “Further Studies of the Infectious Unit of Vaccinia.” J. Exp. Med. 74 (1941): 263–281.
2. Bronson, L. H. and R. F. Parker. “The Neutralization of Vaccine Virus by Immune Serum: Titration by the Intracerebral Inoculation of Mice.” J. Bacteriol. 41 (1941): 56–57.
3. Mackett, M. and G. L. Smith. “Vaccinia Virus Expression Vectors.” J. Gen. Virol. 67 (1986): 2067–2082. PubMed: 3531399.
4. Esposito, J. J., et al. “Vaccinia Virus, Complete Genome.” Direct submission, 24 Feb 2003. GenBank: NC_006998.
5. Salzman, N. P. and E. D. Sebring. “Sequential Formation of Vaccinia Virus Proteins and Viral Deoxyribonucleic Acid Replication.” J. Virol. 1 (1967): 16–23. PubMed: 4248263.
6. Smee, D. F., et al. “Characterization and Treatment of Cidofovir-Resistant Vaccinia (WR Strain) Virus Infections in Cell Culture and in Mice.” Antivir. Chem. Chemother. 16 (2005): 203–211. PubMed: 16004083.
7. Gallego-Gómez, J. C., et al. “Differences in Virus-Induced Cell Morphology and in Virus Maturation between MVA and Other Strains (WR, Ankara, and NYCBH) of Vaccinia Virus in Infected Human Cells.” J. Virol. 77 (2003): 10606–10622. PubMed: 12970445.
8. Ramirez, J. C., M. M. Gherardi, and M. Esteban. “Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a Vaccine.” J. Virol. 74 (2000): 923–933. PubMed: 10623755.
|
|
Citation:
|
Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Vaccinia Virus, Western Reserve (NIAID, Tissue Culture Adapted), NR-55."
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|